The therapeutic antibodies market to 2008

The therapeutic biologics market is currently dominated by recombinant protein products. However, many of these products are mature, and growth of the biologics market will increasingly rely on the expansion of the therapeutic monoclonal antibody sector. Successive technology waves have driven the g...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutics and biopharmaceutics 2005-04, Vol.59 (3), p.389-396
Main Authors: Pavlou, Alex K., Belsey, Mark J.
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - economics
Antibodies, Monoclonal - therapeutic use
Biopharmaceutics - economics
Biopharmaceutics - methods
Biopharmaceutics - trends
Biotechnology - economics
Biotechnology - methods
Biotechnology - trends
Chimeric
Databases, Factual - trends
Fabs
Fully human
Humanized
Humans
Market analysis
Mice
Monoclonal antibody
Murine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The therapeutic biologics market is currently dominated by recombinant protein products. However, many of these products are mature, and growth of the biologics market will increasingly rely on the expansion of the therapeutic monoclonal antibody sector. Successive technology waves have driven the growth of the monoclonal antibody sector, which is currently dominated by chimeric antibodies. Chimeric products, led by Remicade and Rituxan, will continue to drive market share through to 2008. However, over the forecast period, humanized and fully human monoclonal antibodies, together with technologies such as Fabs and conjugated antibodies, will play an increasingly important role, driving monoclonal antibody market growth at a forecast compound annual growth rate of 20.9%, to reach $16.7 billion by 2008. In terms of therapeutic focus, the monoclonal antibody market is heavily focused on oncology and arthritis, immune and inflammatory disorders, and products within these therapeutic areas are set to continue to be the key growth drivers over the forecast period. Underlying the growth of the market is the evolution of the monoclonal antibody company business model, set to transition towards the highly successful innovator model.
ISSN:0939-6411
1873-3441
DOI:10.1016/j.ejpb.2004.11.007